Disc Medicine (NASDAQ:IRON) Releases Earnings Results, Misses Estimates By $0.03 EPS

Disc Medicine (NASDAQ:IRON) posted its quarterly earnings results on Tuesday. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03), FiscalAI reports.

Disc Medicine Stock Performance

Shares of IRON stock traded down $1.12 during trading hours on Thursday, hitting $67.53. The stock had a trading volume of 395,188 shares, compared to its average volume of 606,288. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 21.94. The firm has a market capitalization of $2.58 billion, a PE ratio of -10.20 and a beta of 0.93. The stock’s 50 day moving average is $65.01 and its 200 day moving average is $76.09. Disc Medicine has a twelve month low of $40.00 and a twelve month high of $99.50.

Insider Transactions at Disc Medicine

In related news, CEO John D. Quisel sold 13,264 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $833,775.04. Following the completion of the sale, the chief executive officer owned 226,064 shares in the company, valued at $14,210,383.04. This represents a 5.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jonathan Yen-Wen Yu sold 3,231 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $203,100.66. Following the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at $3,414,806.64. The trade was a 5.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 59,410 shares of company stock worth $3,840,013 over the last 90 days. Company insiders own 3.64% of the company’s stock.

Institutional Trading of Disc Medicine

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRON. RA Capital Management L.P. grew its stake in shares of Disc Medicine by 25.3% in the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after purchasing an additional 399,026 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Disc Medicine by 28.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock worth $134,839,000 after purchasing an additional 371,576 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after purchasing an additional 828,248 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Disc Medicine by 7.7% during the fourth quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company’s stock worth $120,566,000 after purchasing an additional 108,197 shares during the period. Finally, State Street Corp grew its position in Disc Medicine by 13.6% in the 4th quarter. State Street Corp now owns 1,187,991 shares of the company’s stock valued at $94,338,000 after buying an additional 142,394 shares during the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on IRON. Stifel Nicolaus decreased their target price on Disc Medicine from $125.00 to $110.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Wedbush reduced their price objective on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a research report on Tuesday, February 17th. UBS Group reaffirmed an “overweight” rating on shares of Disc Medicine in a research report on Thursday, January 15th. BMO Capital Markets cut their price target on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 17th. Finally, Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Disc Medicine presently has an average rating of “Moderate Buy” and an average target price of $104.80.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.